FGFR alterations detected in solid tumors include FGFR1 amplifications in non-small-cell lung cancer (in 20% of patients), FGFR1/2 amplifications in breast cancer (7-23%), FGFR3 mutations (10%-60%) or FGFR3 fusions (6%) in urothelial carcinoma, FGFR2 fusions in intrahepatic cholangiocarcinoma (10%-20%), FGFR2 mutations in endometrial uterine cancer (12%) and FGFR2 amplifications in gastric cancer (5%-10%), which are representative of the spectrum of FGFR abnormalities in adult cancers[6,36]. This evidence concerns the gene FGFR2 and urothelial carcinoma.